Braveheart Bio, Inc.
BRVE evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $2.15B
What it means
What to watch
Prepared research question
What matters most for BRVE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BRVE
Braveheart Bio, Inc. (BRVE) is a clinical-stage biopharmaceutical company developing BHB-1893, a next-generation therapeutic for obstructive hypertrophic cardiomyopathy (oHCM), with no approved products or product revenue to date.
Key risk: Single-product pipeline
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$2.15B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for Braveheart Bio, Inc..
Braveheart Bio, Inc. (BRVE) is a clinical-stage biopharmaceutical company developing BHB-1893, a next-generation therapeutic for obstructive hypertrophic cardiomyopathy (oHCM), with no approved products or product revenue to date.
- Cash and cash equivalents of $122.8 million as of June 30, 2026, and approximately $527.3 million on a pro forma basis after giving effect to the IPO completed in August 2026 [sec_mda · as of 2026-09-08].
- Net income of -$15.0 million and shareholders' equity of -$95.9 million as of June 30, 2026 [latest reported financials (authoritative, structured)].
- Phase 3 LIONHEART-HCM trial of BHB-1893 in obstructive hypertrophic cardiomyopathy (oHCM) initiated [news · published 2026-09-08].
- No products approved for sale and no revenue generated from product sales [sec_mda · as of 2026-09-08].
- Cash runway estimated to fund projected operating expenses and capital expenditure requirements into 2029 [sec_mda · as of 2026-09-08].
What works
- Cash and cash equivalents of approximately $527.3 million after the IPO are expected to support advancement of BHB-1893 through late-stage clinical development [news · published 2026-09-08].
- The company has initiated a Phase 3 multi-region, multi-center, randomized, double-blind, active-comparator-controlled trial for BHB-1893, indicating progress toward potential registration [catalyst].
- Braveheart Bio has exclusive rights to Hengrui's library of additional myosin-binding compounds, providing potential pipeline expansion opportunities [sec_mda · as of 2026-07-30].
What to weigh
- The company has no approved products and has not generated any revenue from product sales, with expectations of continuing significant expenses and losses for the foreseeable future [sec_mda · as of 2026-09-08].
- Shareholders' equity is negative at -$95.9 million as of June 30, 2026, indicating accumulated deficits exceed contributed capital [latest reported financials (authoritative, structured)].
- The entire pipeline is concentrated on a single product candidate (BHB-1893), which may fail to demonstrate sufficient efficacy or safety, or may not differentiate from existing HCM therapies [sec_mda · as of 2026-07-30].
- If additional capital is needed and cannot be raised on attractive terms, the company may have to delay, reduce, or discontinue development or commercialization of its product candidates [sec_mda · as of 2026-09-08].
From the filings
Quoted directly from source documents.
Cash position after IPO
“Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effect to Braveheart Bio's Initial Public Offering”
News · September 8, 2026
No product revenue
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · September 8, 2026
Phase 3 trial initiation
“Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated”
News · September 8, 2026
Cash runway into 2029
“we estimate that our existing cash and cash equivalents, together with the net proceeds from our IPO completed during the third quarter of 2026, will be sufficient to fund our projected operating expenses and capital expenditure requirements into 2029.”
SEC MD&A · September 8, 2026
Catalyst timeline
- 2026-09-02 · Phase 3 LIONHEART-HCM trial start — Initiation of a multi-region, randomized, double-blind, active-comparator-controlled trial of BHB-1893 versus metoprolol in symptomatic obstructive hypertrophic cardiomyopathy.
Risks & what to watch (4)›
Key risks
- Single-product pipeline — Entire pipeline depends on BHB-1893; failure in efficacy, safety, or differentiation could halt the company [sec_mda · as of 2026-07-30].
- No revenue, ongoing losses — No approved products or product revenue; expects significant expenses and losses for the foreseeable future [sec_mda · as of 2026-09-08].
- Negative shareholders' equity — Shareholders' equity of -$95.9M as of 2026-06-30 indicates accumulated deficits exceed contributed capital [latest reported financials].
- Capital-raising risk — If additional funds cannot be raised on attractive terms, development or commercialization may be delayed or reduced [sec_mda · as of 2026-09-08].
What to watch
- Progress and data readouts from the Phase 3 LIONHEART-HCM trial of BHB-1893 [news · published 2026-09-08].
- Cash burn rate and whether the estimated runway into 2029 holds as expenses increase [sec_mda · as of 2026-09-08].
- Any updates on Hengrui's Phase 2 trial of HRS-1893 in HFpEF, which could inform Braveheart's pipeline expansion [sec_mda · as of 2026-07-30].
- Regulatory interactions and potential NDA submission strategy for BHB-1893 [sec_mda · as of 2026-07-30].
Sources: Catalysts · News · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Braveheart Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Braveheart Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
Net income -$15M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
13 buys · 0 sells (180d)
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Braveheart Bio, Inc.?
Braveheart Bio, Inc. (BRVE) is a clinical-stage biopharmaceutical company developing BHB-1893, a next-generation therapeutic for obstructive hypertrophic cardiomyopathy (oHCM), with no approved products or product revenue to date.
Who is the CEO of Braveheart Bio, Inc.?
Dr. Travis Murdoch B.S., M.D., M.Sc. is the chief executive officer of Braveheart Bio, Inc. (BRVE).
Where is Braveheart Bio, Inc. headquartered?
Braveheart Bio, Inc. (BRVE) is headquartered in San Francisco, CA, United States.
What therapeutic areas does Braveheart Bio, Inc. focus on?
Braveheart Bio, Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.